Key Takeaways
- RefluxStop® sales surged over 60% year-on-year, highlighting strong growth in Europe.
- FDA approval facilitates entry into the U.S. market, alongside expansion of global Centers of Excellence.
- Net sales for the second quarter increased by 66%, although operating losses persist.
Sales Growth and Regulatory Milestones
In the second quarter of 2026, Implantica reported significant commercial momentum for its lead product, RefluxStop®. Sales increased by more than 60% compared to the same period last year, indicating robust growth across key European markets. This product, designed for treating gastroesophageal reflux disease (GERD), has received considerable attention, evidenced by the largest independent study published in *Nature’s Scientific Reports*. This study analyzed safety outcomes for 602 patients across 22 centers in six European countries, revealing minimal serious safety events.
The company bolstered its clinical and health-economic evidence base, which included new cost-effectiveness data from Italy and an additional InEK-reporting hospital in Germany to enhance reimbursement pathways.
Entering the U.S. Market
Following FDA premarket approval, Implantica is poised to launch RefluxStop® in the U.S. The approval opens up significant market opportunities, enabling the company to initiate commercial activities in the region. Alongside this, Implantica is enhancing its U.S. organization and establishing logistics and distribution systems.
Furthermore, the European network continues to thrive, reaching over 60 Centers of Excellence, with notable new additions in Spain, Switzerland, and the UK.
Financial Overview
Financially, the second quarter recorded net sales of TEUR 717, marking a 66% increase from TEUR 433 in the same quarter last year. The adjusted gross margin stood at 94%, an increase from 90%. However, operating losses decreased slightly to TEUR 4,200 compared to TEUR 4,525 from the previous year. The loss after tax was TEUR 3,987, down from TEUR 5,448.
In the first half of 2026, net sales totaled TEUR 1,574, showing a 34% increase from TEUR 1,178. The adjusted gross margin remained strong at 94%, but the operating loss for the half-year declined only marginally, leading to a total loss after tax of TEUR 8,267, slightly up from TEUR 8,212.
Future Outlook and Engagement
To discuss the latest developments and future prospects, Implantica will hold a teleconference on August 21, 2026, featuring CEO Peter Forsell and CFO Andreas Öhrnberg. Participants can join via registration and will receive information about the conference ID and dial-in details.
Implantica is focused on advancing its robust pipeline of implantable technologies aimed at improving patient outcomes and quality of life. In addition to RefluxStop®, the company is exploring innovative platforms for eHealth communication and wireless device energization.
Implantica is publicly traded on the Nasdaq First North Premier Growth Market, cementing its position as a key player in the medtech industry.
The content above is a summary. For more details, see the source article.
